NEW ORLEANS – At the annual meeting of the American Association for Cancer Research (AACR), data from several new studies showed progress toward the wish of their developers, as expressed by Yervoy (ipilimumab, Bristol Myers Squibb Co.) developer James Allison at the 2012 annual meeting: "Get that tail up."